Abstract
Fast testing can help mitigate the coronavirus disease 2019 (COVID-19) pandemic. Despite their accuracy for single sample analysis, infectious diseases diagnostic tools, like RT-PCR, require substantial resources to test large populations. We develop a scalable approach for determining the viral status of pooled patient samples. Our approach converts group testing to a linear inverse problem, where false positives and negatives are interpreted as generated by a noisy communication channel, and a message passing algorithm estimates the illness status of patients. Numerical results reveal that our approach estimates patient illness using fewer pooled measurements than existing noisy group testing algorithms. Our approach can easily be extended to various applications, including where false negatives must be minimized. Finally, in a Utopian world we would have collaborated with RT-PCR experts; it is difficult to form such connections during a pandemic. We welcome new collaborators to reach out and help improve this work!
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
The work of Baron was supported in part by NSF EECS #1611112. Rivera was supported by the National Institutes of Health under award number F31DK118859-02 and by the 2019 Howard Hughes Medical Institute Gilliam Fellowship Award.
Author Declarations
All relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.
Yes
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
The work of Baron was supported in part by NSF EECS #1611112. Rivera was supported by the National Institutes of Health under award number F31DK118859-02 and by the 2019 Howard Hughes Medical Institute Gilliam Fellowship Award.
1 AMP can be derived from GAMP for a specific setting [7]. While AMP [9] requires the matrices it processes to have zero mean, GAMP is less restrictive.
2 Our GAMP-based algorithm is relatively fast; problems of size (M = 1500, N = 5000) take a few seconds to run on a laptop computer.
3 The parameters p1 and p2 resemble Hanel and Thurner [3]; other sources suggest larger false positive and negative probabilities. For our software, these are merely parameters that are easily modified.
Data Availability
We have not carried out any clinical trials and so the paper does not contain such data. We will put related simulation data our website https://people.engr.ncsu.edu/dzbaron/.
